Search results
Author(s):
Aruna D Pradhan
,
Gurleen Kaur
Added:
1 year ago
AHA 22 - Dr Gurleen Kaur, Director of the CardioNerds Internship(Brigham and Women's Hospital, US) joins us in this collaboration between the @CardioNerds and Radcliffe Cardiology to interview Dr Aruna Pradhan (Brigham and Women's Hospital, US), study director of the PROMINENT trial (NCT03071692)on the late-breaking data from AHA 2022.
PROMINENT was a multicenter randomized trial aiming to…
View more
Author(s):
Anandita Agarwala
,
Michael D Shapiro
Added:
3 years ago
Atherogenic dyslipidaemia encompasses a broad variety of lipid phenotypes. While LDL cholesterol is a well-known risk factor for atherosclerotic cardiovascular disease (ASCVD), there are additional atherogenic lipoproteins that may be targeted to further reduce ASCVD risk.
In their comprehensive review, Lorenzatti and Toth emphasise that, even when LDL cholesterol levels are optimised, ASCVD…
View more
Author(s):
Ewa Dembowski
,
Michael H Davidson
Added:
3 years ago
Pharmacological regulation of lipid metabolism in patients with dyslipidaemia is undeniably associated with significant reductions in risk of cardiovascular (CV) morbidity and mortality. There are strong clinical trial data to support the use of lipid-lowering therapies in the settings of both primary and secondary prevention. Statins and fibrates are two classes of drug that have demonstrated…
View more
AHA 2018: REDUCE-IT
Author(s):
Pradeep Natarajan
Added:
5 years ago
Video
Dyslipidaemia in the Real World
Author(s):
Ricardo Lopez Santi
,
Felipe Martínez
,
Adrian Baranchuk
,
et al
Added:
2 years ago
Article
Author(s):
Jean-Claude Tardif
Added:
3 years ago
Dr Jean-Claude Tardif (Montreal Heart Institute, Montreal, CA) discusses the effects of Apolipoprotein C-III (ApoC-III) reduction in cardiovascular (CV) disease. The administration of APOCIII-LRX in patients with hypertriglyceridemia and high CV risk was associated with inhibition of ApoC-III and lower levels of triglycerides.
Questions:
1. What is the background of this study?
2. What was the…
View more
Remnant Lipoproteins and ASCVD
Author(s):
Mohanad Gabani
,
Michael D Shapiro
,
Peter P Toth
Added:
6 months ago
Article
Author(s):
Alberto Lorenzatti
,
Peter P Toth
Added:
3 years ago
We are witnessing an epidemic global increase in the prevalence of obesity and its clinical consequences (e.g. insulin resistance and diabetes). This epidemic has been potentiated and sustained by the widespread adoption of unhealthy lifestyles in broad swathes of the population and is characterised by a sedentary lifestyle and an imbalance between the type and characteristics of nutrition,…
View more
Michael D Shapiro
Research Area(s) / Expertise:
Job title: Director of the Center for Preventive Cardiology
Author
Author(s):
Alejandro de la Sierra
Added:
3 years ago
The Concepts of Metabolic Syndrome and Cardiometabolic Risk
Cardiometabolic risk represents a situation where the possibilities of developing atherosclerotic cardiovascular disease and diabetes are significantly enhanced as a consequence of the presence of insulin resistance and atherogenic dyslipidaemia. Dyslipidaemia is characterised by the presence of low high-density lipoprotein (HDL)…
View more